These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30348741)

  • 1. Diagnosing ovarian cancer.
    Walker M; Sobel M
    CMAJ; 2018 Oct; 190(42):E1259. PubMed ID: 30348741
    [No Abstract]   [Full Text] [Related]  

  • 2. Cancer antigen 125 level after a bilateral salpingo-oophorectomy: what is the contribution of the ovary to the cancer antigen 125 level?
    van Altena AM; Holtsema H; Hendriks JC; Massuger LF; de Hullu JA
    Menopause; 2011 Feb; 18(2):133-7. PubMed ID: 20861755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing.
    Schwartz MD; Kaufman E; Peshkin BN; Isaacs C; Hughes C; DeMarco T; Finch C; Lerman C
    J Clin Oncol; 2003 Nov; 21(21):4034-41. PubMed ID: 14581427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of ovarian cancer risk in women with
    Walker M; Jacobson M; Sobel M
    CMAJ; 2019 Aug; 191(32):E886-E893. PubMed ID: 31405835
    [No Abstract]   [Full Text] [Related]  

  • 5. Ovarian cancer screening in the high-risk population--the UK Familial Ovarian Cancer Screening Study (UKFOCSS).
    Rosenthal AN
    Int J Gynecol Cancer; 2012 May; 22 Suppl 1():S27-8. PubMed ID: 22543917
    [No Abstract]   [Full Text] [Related]  

  • 6. Cancer of the ovary.
    Cannistra SA
    N Engl J Med; 2004 Dec; 351(24):2519-29. PubMed ID: 15590954
    [No Abstract]   [Full Text] [Related]  

  • 7. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers.
    Evans DG; Gaarenstroom KN; Stirling D; Shenton A; Maehle L; Dørum A; Steel M; Lalloo F; Apold J; Porteous ME; Vasen HF; van Asperen CJ; Moller P
    J Med Genet; 2009 Sep; 46(9):593-7. PubMed ID: 18413372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA125 screening after risk-reducing salpingo-oophorectomy: are the titers too high, or is it all just too much?
    Bradford LS; Schorge JO
    Menopause; 2011 Feb; 18(2):123-4. PubMed ID: 21191312
    [No Abstract]   [Full Text] [Related]  

  • 9. Estimating the risk of ovarian cancer.
    Ebell MH
    Am Fam Physician; 2009 Sep; 80(6):632-4. PubMed ID: 19817330
    [No Abstract]   [Full Text] [Related]  

  • 10. Epithelial ovarian cancer.
    Al-Niaimi AN; Ahmed M; Petersen CB
    Obstet Gynecol Clin North Am; 2012 Jun; 39(2):269-83. PubMed ID: 22640715
    [No Abstract]   [Full Text] [Related]  

  • 11. A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass.
    Kaijser J; Van Gorp T; Van Hoorde K; Van Holsbeke C; Sayasneh A; Vergote I; Bourne T; Timmerman D; Van Calster B
    Gynecol Oncol; 2013 May; 129(2):377-83. PubMed ID: 23360924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretest genetic counseling informs patients with BRCA mutation.
    Printz C
    Cancer; 2012 Dec; 118(24):6017. PubMed ID: 23208671
    [No Abstract]   [Full Text] [Related]  

  • 13. Genetic testing by cancer site: ovary.
    Weissman SM; Weiss SM; Newlin AC
    Cancer J; 2012; 18(4):320-7. PubMed ID: 22846732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Serum tumor markers CA125 and HE4 in ovarian cancer patients].
    Sergeeva NS; Marshutina NV; Alentov II; Korneeva IA; Novikova EG
    Vopr Onkol; 2013; 59(2):12-21. PubMed ID: 23814844
    [No Abstract]   [Full Text] [Related]  

  • 15. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
    Burke W; Daly M; Garber J; Botkin J; Kahn MJ; Lynch P; McTiernan A; Offit K; Perlman J; Petersen G; Thomson E; Varricchio C
    JAMA; 1997 Mar; 277(12):997-1003. PubMed ID: 9091675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary breast and ovarian cancers.
    Herman LM;
    JAAPA; 2008 May; 21(5):18, 21. PubMed ID: 18556884
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
    JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
    Weren RD; Mensenkamp AR; Simons M; Eijkelenboom A; Sie AS; Ouchene H; van Asseldonk M; Gomez-Garcia EB; Blok MJ; de Hullu JA; Nelen MR; Hoischen A; Bulten J; Tops BB; Hoogerbrugge N; Ligtenberg MJ
    Hum Mutat; 2017 Feb; 38(2):226-235. PubMed ID: 27767231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
    Hermsen BB; von Mensdorff-Pouilly S; Berkhof J; van Diest PJ; Gille JJ; Menko FH; Blankenstein MA; Kenemans P; Verheijen RH
    J Clin Oncol; 2007 Apr; 25(11):1383-9. PubMed ID: 17416858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
    Shulman LP
    Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.